R&D Sorrento a konsantre sou kondwi inovasyon nan COVID-19, tretman kansè, kontwòl total doulè ak maladi otoiminitè.

Pwogram kle yo	Endikasyon	Presiklik	Faz I.	Faz II	Faz III/Pivotal	FDA Apwobasyon
Pwogram COVID-19
COVISTIX™ (dyagnostik) Rapid tès antijèn 0%* Otorizasyon pou itilize ijans (EUA) nan Meksik (COFEPRIS), Brezil (ANVISA), ak CE make an Ewòp COVIMARK™ (dyagnostik) Rapid tès antijèn 0%* Aplikasyon yo te soumèt Ozetazini ak Kanada pou Otorizasyon Itilizasyon Ijans (EUA) VIREX (dyagnostik) Dyagnostik lakay ou 60.2%* EUA Enabling Studies in Q3 2022 OQORY™ (COVI-MSC) ARDS akòz COVID-19 nan Pasyan ICU 82%* Pivotal Jijman nan Brezil                           OVYDSO (Olgotrelvir) Anti-viral (Grenn oral) 40%* Vaksen mRNA Omicron Vaksen 20%*
Pwogram kle yo	Endikasyon	Presiklik	Faz I.	Faz II	Faz III/Pivotal	FDA Apwobasyon
imunoterapi
FUJOVEE™ (Abivertinib) NSCLC 82%* FUJOVEE™ (Abivertinib) Lenfom selil B 60.2%* FUJOVEE™ (Abivertinib) Pwostat 20%* PD-L1 (Socazolimab)* SCLC 82%* *An patenarya ak Lee's Pharm nan peyi Lachin PD-L1 (STI-3031)** Kansè nan matris 82%* **Ozetazini ak an patenarya ak ImmuneOncia nan Kore di CD47 Timè solid 40%* CD38 DAR-T Plizyè myeloma 40%* CD38 ADC Amyloidoz, miltip myeloma, T-ALL, ak èzofaj 40%* TROP2 ADC* Timè solid 40%* Seprehvec™ viris onkolitik timè solid; Timè CNS 40%* BCMA ADC Timè likid 20%* Bevacizumab-ADNAB™ Endometrial Kansè 40%* An patenarya ak Mayo Clinic Bevacizumab-ADNAB™ Kansè ovè 40%* An patenarya ak Mayo Clinic Rituximab-ADNAB™ Lenfom selil B 40%* An patenarya ak Mayo Clinic Sofusa® anti-PD-1 Lenfom T-Selil Cutane (CTCL), Melanom 40%*
Pwogram kle yo	Endikasyon	Presiklik	Faz I.	Faz II	Faz III/Pivotal	FDA Apwobasyon
Doulè
ZTlido® 1.8% Postherpetic Neuralji - PHN 99.8%* Gloerba® Tretman pou gout (oral) 99.8%* SEMDEXA (SP-102) Lonbèr Radikilè/Syatik Doulè 82%* SP-103 (Lidokayin Topical System 5.4%) Doulè nan do 60.2%* SP-104 (Reta Pete Dòz ba Naltrexone) Fibromyalji 20%* RTX (resiniferatoxin) Piki epidural Doulè intractable nan kansè avanse 60.3%* Deziyasyon òfelen RTX (resiniferatoxin) Wout Entra-artikulèr Doulè OA nan jenou modere rive grav 60.2%*
Pwogram kle yo	Endikasyon	Presiklik	Faz I.	Faz II	Faz III/Pivotal	FDA Apwobasyon
Akouchman dwòg lenfatik
Sofusa® anti-TNF Otoiminitè (RA) 40%* Sofusa® anti-PD-1 Lenfom T-Selil Cutane (CTCL), Melanom 40%* Sofusa® anti-CTLA-4 Melanoma 40%* An patenarya ak Mayo Clinic

Pwogram COVID-19
Pwogram kle yo (Endikasyon)	Faz
COVISTIX™ (dyagnostik) FDA USA COVIMARK™ (dyagnostik) FDA USA VIREX (dyagnostik) PH III FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III OVYDSO (Olgotrelvir) Ph II Vaksen mRNA Omicron Presiklik

imunoterapi
Pwogram kle yo (Endikasyon)	Faz
FUJOVEE™ (Abivertinib) Ph III FUJOVEE™ (Abivertinib) Ph II FUJOVEE™ (Abivertinib) Presiklik PD-L1 (Socazolimab)* Ph III PD-L1 (STI-3031)** Ph III CD47 (Timè Solid) Ph I CD38 DAR-T (Miltip miltip) Ph I CD38 ADC (Amyloidoz, miltip Myeloma, T-ALL, ak èzofaj) Ph I TROP2 ADC* (Timè Solid) Ph I Seprehvec™ viris onkolitik (Timè Solid; Timè CNS) PH I BCMA ADC (Timè likid) Presiklik Bevacizumab-ADNAB™ (Kansè andomèt) Ph I Bevacizumab-ADNAB™ (Kansè ovè) Ph I Rituximab-ADNAB™ (Lenfom selil B) Ph I Sofusa® anti-PD-1 (Lenfom T-Selil Kutane (CTCL), Melanom) Ph I

Doulè
Pwogram kle yo (Endikasyon)	Faz
ZTlido® 1.8% (Postherpetic Neuralji - PHN) FDA Apwobasyon Gloerba® 1.8% Tretman pou gout (oral) FDA Apwobasyon SEMDEXA (SP-102) Ph III SP-103 (Lidokayin Topical System 5.4%) Ph II SP-104 (Reta Pete Dòz ba Naltrexone) Presiklik RTX (resiniferatoxin) Piki epidural Ph II RTX (resiniferatoxin) Wout Entra-artikulèr Ph II

Akouchman lenfatik
Pwogram kle yo (Endikasyon)	Faz II
Sofusa® anti-TNF (RA otoiminitè) Ph I Sofusa® anti-PD-1 (Lenfom T-Selil Kutane (CTCL), Melanom) Ph I Sofusa® anti-CTLA-4 (Melanom) Ph I